Business
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting the company’s unique,
About this update from Veracyte, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.\n\n“Veracyte’s comprehensive multi-omics expertise and tools provide our biopharma partners with actionable insights to help them confidently advance every step of their oncology drug development programs,” said Corinne Danan, general manager of Veracyte’s Biopharma business unit. “The abstracts accepted for presentation at AACR 2023 will highlight new learnings and tools that demonstrate our ongoing commitment to continually enhancing and expanding the services available to these partners.”\n\nFollowing are details of the Veracyte abstracts that will be shared during poster sessions at the AACR Annual Meeting 2023:\n\n\n\nTitle:\n\n\n\n\nDeciphering the tumor microenvironment at single-cell resolution using a workflow combining RNA transcript and protein detection with Brightplex®, a sequential chromogenic multiplex assay\n\n\n\n\n\nPresenter:\n\n\n\n \n\n\n\nJacques Fieschi, Ph.D., Veracyte\n\n\n\n\n\nDate/Time:\n\n\n\n \n\n\n\nTuesday, April 18, 1:30-5:00 p.m. ET\n\n\n\n\n\nLocation:\n\n\n\n \n\n\n\nPoster Section 4\n\n\n\n\n\nPoster #:\n\n\n\n \n\n\n\n14\n\n\n\n\n\nAbstract #:\n\n\n\n \n\n\n\n4624\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nTitle:\n\n\n\n \n\n\n\nVeracyte Biopharma Atlas for colorectal cancer: combining multi-parameter approach and machine learning to capture the complexity of the tumor immune contexture.\n\n\n\n\n\nPresenter:\n\n\n\n \n\n\n\nFlorence Monville, Ph.D., Research Discovery, Veracyte\n\n\n\n\n\nDate/Time:\n\n\n\n \n\n\n\nTuesday, April 18, 1:30-5:00 p.m. ET\n\n\n\n\n\nLocation:\n\n\n\n \n\n\n\nPoster Section 37\n\n\n\n\n\nPoster #:\n\n\n\n \n\n\n\n26\n\n\n\n\n\nAbstract #:\n\n\n\n \n\n\n\n5476\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nTitle:\n\n\n\n \n\n\n\nDefining the cancer Immunogram using multimodal analysis to guide immunotherapy in diffuse large B cell lymphoma\n\n\n\n\n\nPresenter:\n\n\n\n \n\n\n\nRégis Perbost, Ph.D., Veracyte and Mike Mattie, Ph.D., Kite a Gilead company\n\n\n\n\n\nDate/T...